The ATS 2025 International Conference offers a robust scientific program highlighting cutting-edge advancements in pulmonary, critical care, and sleep medicine. This includes several Postgraduate Courses, Scientific Symposia, and Meet the Expert Sessions addressing new developments and considerations in bronchiectasis and COPD, as listed below. A curated list of clinical and scientific sessions related to these topics is also available on the ATS365 platform. For more information on these and other sessions to be presented May 16–21 in San Francisco, visit the online Advance Program.
- A1 CLINICAL YEAR IN REVIEW
- A102 PHYSIOLOGY AND IMAGING IN AIRWAY DISEASE
- A104 REVOLUTIONIZING PULMONARY AND CRITICAL CARE: THE IMPACT OF NURSE-LED RESEARCH
- A107 NOVEL THERAPIES AND MOLECULAR PATHWAYS IN COPD, AATD, AND AIRWAY REGENERATION
- A108 ALL THAT’S WICKED IN ASTHMA
- A11 CENTENNIAL CELEBRATION OF VA’S RESEARCH AND DEVELOPMENT PROGRAM
- A12 IMPLEMENTING PREVENTATIVE AND BEHAVIORAL HEALTH INTERVENTIONS IN PULMONARY MEDICINE
- A15 PRIMARY AND SECONDARY RESULTS FROM CLINICAL TRIALS: COPD AND PLEURAL DISEASE
- A16 BEYOND THE DUST: ADVANCING EXPOSURE ASSESSMENT, METABOLOMICS, AND TREATMENT IN OCCUPATIONAL LUNG DISEASES
- A18 BEST TRIALS IN PULMONARY REHABILITATION
- A30 BIOMARKERS, PREDICTORS, AND MODIFIERS OF PEDIATRIC PULMONARY OUTCOMES
- A31 THE EVOLVING LANDSCAPE OF BRONCHOPULMONARY DYSPLASIA: MAKING STRIDES
- A34 WINNING THE BIOLOGIC BATTLE IN ASTHMA AND COPD
- A6 EVOLVING LANDSCAPE OF RESPIRATORY OUTCOMES IN SURVIVORS OF PREMATURE BIRTH
- A68 EXPANDING HORIZONS IN PULMONARY REHABILITATION: NOVEL APPLICATIONS, OUTCOMES, AND INNOVATIONS
- A69 EMERGING MOLECULAR PATHWAYS IN ACUTE LUNG INJURY AND PULMONARY INFLAMMATION
- A70 GENE EXPRESSION, METABOLISM AND EPITHELIAL DYSFUNCTION IN AIRWAY DISEASES: FROM ASTHMA TO COPD
- A71 EPITHELIAL DYSFUNCTION, INFLAMMATION AND CIGARETTE SMOKE: DRIVERS OF COPD AND CF PATHOGENESIS
- A73 CLINICAL REPORTS I: STRUCTURAL CURIOSITIES
- A75 RUNNING DIAGNOSTICS: WHAT’S NEW IN LUNG PHYSIOLOGY?
- A76 FINGER ON THE PULSE: CARDIOPULMONARY DYSFUNCTION IN LUNG DISEASE
- A8 EMPHYSEMA ACROSS DISEASES: FLAWED (RE)GENERATION OR RAPID DESTRUCTION?
- A84 NAVIGATING THE NEW LANDSCAPE IN HOME VENTILATION
- A87 VIRTUAL PULMONARY REHABILITATION: CAN WE GET TO CONSENSUS? A PRO/CON DEBATE
- A88 EPIGENETICS: HOW EARLY LIFE EXPOSURES CONTRIBUTE TO LUNG DISEASE LATER IN LIFE
- A9 ADVANCING HOST-DIRECTED THERAPIES IN PULMONARY INFECTIONS: BRIDGING RESEARCH AND CLINICAL PRACTICE
- A91 HOW TO ACHIEVE GLOBAL EQUITY IN MEDICATION ACCESS FOR CHRONIC RESPIRATORY DISEASES: CHALLENGES AND OPPORTUNITIES
- A94 DISPARITIES IN COPD, RESPIRATORY INFECTIONS, LUNG CANCER SCREENING AND OTHER AREAS
- B1 CLINICAL YEAR IN REVIEW
- B101 FIXING BARRIERS: UNLOCKING TREATMENT MODALITIES IN INFLAMMATORY LUNG DISEASES
- B105 PULMONARY FUNCTION TESTING, IMAGING, AND DIAGNOSTIC TOOLS FOR PEDIATRIC PULMONARY DISEASES
- B107 WHAT’S NEW IN PULMONARY REHABILITATION ASSESSMENT STRATEGIES?
- B108 INNOVATIVE INSIGHTS INTO LUNG INJURY: FROM INFLAMMATION TO BARRIER RESTORATION
- B17 THE POWER OF TEAM SCIENCE: INTERDISCIPLINARY APPROACHES TO PULMONARY AND CRITICAL CARE
- B21 EQUITY, EFFECTIVENESS AND EXPERIENCE IN PR
- B29 AIRWAY AND ALVEOLAR EPITHELIAL RESPONSES: FROM INJURY MECHANISMS TO REGENERATIVE POTENTIAL
- B30 ADVANCED MODALITIES TO UNCOVER PATHOPHYSIOLOGIC FEATURES IN COPD
- B34 BREATH-TAKING MECHANISMS IN COPD
- B35 ‘OMICS AND OUTCOMES: TRANSLATIONAL STUDIES ACROSS LUNG DISEASES
- B5 REMINISCENCE OF AN EARLIER LIFE – SHEDDING MECHANISTIC LIGHT ON THE TRANSGENERATIONAL IMPACT OF CIGARETTE SMOKE ON LUNG FUNCTION
- B60 ADVANCING PATIENT CARE: THE INTERCONNECTION OF TRAINING, PERSPECTIVES, AND CLINICAL RESULTS IN RESPIRATORY HEALTH
- B7 CLEAR SKIES OR HAZY HORIZONS: DEBATING PERSONAL POLLUTION CONTROL
- B76 CLINICAL REPORTS II: UNUSUAL SUSPECTS
- B79 SLEEP BY THE NUMBERS: TRACKING RISKS, OUTCOMES, AND REAL-WORLD IMPACT
- B8 PULMONARY VIRUS INFECTIONS ACROSS THE LIFESPAN
- B84 DIAGNOSIS OF COPD: A PRO CON DEBATE
- B85 OBSTRUCTIVE AIRWAY AND LUNG DISEASE BEGINS IN THE WOMB
- B88 NOVEL MANAGEMENT STRATEGIES IN BRONCHIECTASIS
- B90 UNSEEN YET CRITICAL: SMALL AIRWAYS IN CHRONIC AIRWAY DISEASES
- B93 COPD EPIDEMIOLOGY AND MANAGEMENT
- B95 OMICS CONTINUE TO IDENTIFY MECHANISMS UNDERLYING CHILDHOOD LUNG DISEASES
- B98 CELLULAR INTERACTIONS AND SIGNALING NETWORKS IN PULMONARY FIBROSIS
- B99 IDENTIFYING SIGNATURES OF DYSFUNCTION IN COPD
- C1 CLINICAL YEAR IN REVIEW
- C101 ASTHMA AND COPD EPIDEMIOLOGY, MANAGEMENT AND POLICY
- C102 PACING LIFE SUPPORT IN THE ICU: PREDICTORS, PRACTICES, AND PATIENT OUTCOMES IN ACUTE RESPIRATORY FAILURE
- C108 OPTIMIZING THE IMPACT OF PULMONARY REHABILITATION
- C109 IMMUNE AND CELLULAR MECHANISMS DRIVING AIRWAY DISEASES: FROM INFLAMMATION TO METABOLISM
- C11 MICROPLASTICS AND THEIR IMPACT ON HEALTH
- C14 STRENGTHENING YOUR “-ABS”: CLINICAL THERAPEUTICS FOR INFLAMMATORY LUNG DISEASE
- C15 ‘OMICS ODYSSEY ACROSS LUNG DISEASES
- C18 SPATIAL AND SINGLE-CELL ANALYSIS OF LUNG DISEASE: BRIDGING EARLY MECHANISMS TO THERAPEUTIC GAPS
- C2 TYPE 2 INFLAMMATION IN COPD: A PRO AND CON DEBATE
- C22 BIG DATA AND TECHNOLOGY IN RESPIRATORY MEDICINE
- C27 GENETICS AND -OMICS TO PREDICT AND UNDERSTAND CHILDHOOD LUNG DISEASES
- C7 NEXT STEPS: ENHANCING RESEARCH TRIALS IN PULMONARY REHABILITATION TO IMPROVE REAL WORLD IMPLEMENTATION
- C73 ENVIRONMENTAL STRESSORS AND MOLECULAR MECHANISMS DRIVING LUNG INJURY AND DISEASE PATHOGENESIS
- C75 COPD: STRUCTURE AND FUNCTION
- C82 COPD CLINICAL TRIALS – WHERE DO WE GO FROM HERE?
- C88 YES, A WHOLE SESSION ON MUCUS: LATEST RESEARCH INSIGHTS
- C89 FROM AIR TO AILMENTS: UNDERSTANDING THE IMPACT OF AIRBORNE POLLUTANTS AND PARTICULATE MATTER FROM DIFFERENT SOURCES ON HEALTH
- C9 MANY FACES OF ALVEOLAR TYPE II CELLS- PLASTICITY IN HEALTH AND DISEASE
- C97 CUTTING-EDGE ADVANCES IN PEDIATRIC LUNG DISEASES: FROM PREDICTION TO MANAGEMENT
- C99 THE ALVEOLAR NICHE AND EPITHELIAL REMODELING IN EARLY AND ADVANCED FIBROSIS
- D101 DISCOVERY OMICS AND COMPUTATIONAL STRATEGIES IN LUNG DISEASE RESEARCH
- D107 FROM HIDDEN CULPRITS TO DIAGNOSTIC BREAKTHROUGHS: UNIQUE INFECTIOUS DISEASE CASES
- D108 CELLULAR FATE, HOST-PATHOGEN INTERACTIONS, AND ENVIRONMENTAL INFLUENCES IN AIRWAY DISEASE
- D109 THE NEW NORMAL? EARLY SIGNS OF CHRONIC LUNG DISEASE
- D11 LONG-TERM CONSEQUENCES OF RESPIRATORY VIRAL INFECTIONS AND CHRONIC PULMONARY DISEASES: LONG-COVID, ASTHMA, ILD AND LUNG TRANSPLANT
- D16 INDOOR/OUTDOOR AIR POLLUTION: UNCOVERING DISPARITIES AND ADVANCING LUNG HEALTH
- D17 MITOCHONDRIAL AND EPITHELIAL DYNAMICS IN CHRONIC AND ACUTE LUNG DISEASE
- D18 CLEARING THE WAY: OPTIMIZING THERAPIES FOR MUCOCILIARY DISEASES
- D19 IN THE SHALLOW: EXPLORING SLEEP RELATED HYPOVENTILATION DISORDERS
- D23 BEST CASE REPORTS IN CHRONIC LUNG DISEASE
- D27 CELLULAR MECHANISMS AND IMMUNE PATHWAYS UNDERLYING PEDIATRIC PULMONARY DISEASES
- D29 FROM BENCH TO BEDSIDE: UNRAVELING PULMONARY FIBROSIS THROUGH CELLULAR COMMUNICATION AND MOLECULAR PATHWAYS
- D30 GOING WITH THE FLOW: ABNORMALITIES IN RESPIRATORY MECHANICS
- D82 RESPIRATORY CONVERSATIONS: ADVANCES IN ORGAN-ORGAN CROSSTALK IN PULMONARY PATHOBIOLOGY
- D83 POST-INFECTIOUS PULMONARY COMPLICATIONS: TB, SARS-COV-2, AND BEYOND
- D94 INROADS INTO NOVEL THERAPEUTICS AND DELIVERY APPROACHES FOR PEDIATRIC LUNG DISEASES
- D96 PNEUMONIA’S SECRET RECIPE: A PINCH OF MICROBIOME, A DASH OF HOST FACTORS, AND A SHOT OF VACCINE
- D97 IMMUNE-EPITHELIAL INTERACTIONS AND LUNG REPAIR IN INJURY AND REPAIR
- IPC3 Smoking and Vaping: Role of Respiratory Societies in Global Prevention
- IPC4 Quality Management of Chronic Respiratory Diseases in Resource-Constrained Countries
- IPC5 Buenos Dias ATS – COPD: Moving Towards a New Era
- MD11 COPDGENE: A 15-YEAR LONGITUDINAL STUDY UNRAVELING COPD PROGRESSION AND HEALTH OUTCOMES
- MD12 LUNGMAP PHASE 3- NOVEL TECHNOLOGY, DATA SCIENCE, AND RESOURCES
- MD16 RED JOURNAL IN ACTION 2: AIRWAYS MEET NEUROSCIENCE PERSPECTIVES
- MD17 PCORI-FUNDED PULMONARY & CRITICAL CARE TRIALS
- MD18 IMPROVING COPD CARE QUALITY USING IMPLEMENTATION SCIENCE METHODS
- MD2 STUDY UPDATES FROM THE AMERICAN LUNG ASSOCIATION’S AIRWAY CLINICAL RESEARCH CENTERS NETWORK
- MD21 50 YEARS OF SUPPORTING LUNG RESEARCH: THE PARKER B. FRANCIS FELLOWSHIP
- MD25 INSIGHTS FROM THE SUBPOPULATIONS AND INTERMEDIATE OUTCOMES IN COPD STUDY (SPIROMICS ) FAMILY OF STUDIES: EARLY DATA AND FUTURE PLANS
- MD30 MICRO AND NANOPLASTICS HEALTH EFFECTS: WHAT WE KNOW OR DON’T
- MD31 LUNGMAP PHASE 3- HIGH RESOLUTION MOLECULAR PROFILING OF LUNG DISEASES
- MD34 ARTIFICIAL INTELLIGENCE ON CHEST CT TO IMPROVE THE DEFINITION OF LUNG DISEASES AND THEIR SUBTYPES
- MD7 CARDIOPULMONARY FAILURE IN COPD: INSIGHTS FROM THE SUBPOPULATIONS AND INTERMEDIATE OUTCOMES IN COPD AND HEART FAILURE STUDY (SPIROMICS HF)
- MTE17 TWO BAD DISEASES ARE WORSE THAN ONE: PULMONARY HYPERTENSION IN ILD AND COPD
- MTE2 MAKING WAVES: OSCILLOMETRY BASICS AND INTERPRETATION FOR CLINICAL AND RESEARCH APPLICATION
- MTE20 GENERATIVE AI FOR LUNG IMAGING AND DISEASE DIAGNOSIS
- MTE25 IMMUNOLOGIC UNDERPINNINGS OF COPD
- MTE27 BRONCHIECTASIS: FOLLOWING THE UPDATED GUIDELINES AND ASSESSING NEW THERAPEUTICS
- MTE29 ARTIFICIAL INTELLIGENCE AND THE FUTURE OF PULMONARY MEDICINE
- MTE4 BRONCHIECTASIS – MORE THAN A CASE OF CHRONIC COUGH
- MTE5 THE EVALUATION OF RECURRENT PULMONARY INFECTIONS: IDENTIFICATION OF PRIMARY IMMUNODEFIENCY AND DIFFERENTIAL DIAGNOSIS
- PG10 PULMONARY FUNCTION TESTING: STATE OF THE ART IN 2025
- PG13 LUNG IMMUNITY AND RESPIRATORY INFECTION
- PG14 UPDATES ON LUNG TRANSPLANTATION: WHAT PULMONOLOGISTS NEED TO KNOW
- PG15 INTEGRATIVE LUNG BIOINFORMATICS: FROM DATA TO DISCOVERY
- PG16 CARDIOPULMONARY EXERCISE TESTING: ADVANCES AND APPLICATIONS
- PG17 OCCUPATIONAL AND ENVIRONMENTAL LUNG DISEASE 101: DOES MY PATIENT HAVE OCCUPATIONAL LUNG DISEASE?
- PG2 BRONCH DAY 2025: A COMPREHENSIVE, HANDS-ON GUIDE TO BASIC BRONCHOSCOPY, EBUS, AND GUIDED BRONCHOSCOPY
- PG3 ADVANCES IN THE MANAGEMENT OF COMPLEX SLEEP-DISORDERED BREATHING AND CHRONIC RESPIRATORY FAILURE
- PG7 A HANDS-ON INTRODUCTION TO STUDYING THE LUNG MICROBIOME
- PG8 INNOVATIVE PRECLINICAL MODELS FOR HUMAN LUNG RESEARCH: BRIDGING THE GAP FROM BENCH TO BEDSIDE
Extend Your Learning Beyond San Francisco with ATS 2025 Conference Highlights
With so many valuable educational opportunities offered during the ATS 2025 International Conference, attendees are often forced to decide which sessions to prioritize. That’s why the Society is offering three ATS 2025 Conference Highlights packages for those unable to attend ATS 2025 San Francisco or attendees interested in continuing their education after the conference. Check out the packages and pick the one that’s right for you. Learn at your own pace, whenever and wherever you are!